KRON Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -595.27% compared to Kronos Bio's net margin of --. Kronos Bio's return on equity of -60.36% beat CEL-SCI's return on equity of --.

Kronos Bio has a consensus price target of --, signalling upside risk potential of 125%. On the other hand CEL-SCI has an analysts' consensus of $7.73 which suggests that it could grow by 1694.28%. Given that CEL-SCI has higher upside potential than Kronos Bio, analysts believe CEL-SCI is more attractive than Kronos Bio.

Kronos Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.718%.

Kronos Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kronos Bio pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Kronos Bio quarterly revenues are $2.4M, which are larger than CEL-SCI quarterly revenues of --. Kronos Bio's net income of -$14.1M is lower than CEL-SCI's net income of -$6.9M. Notably, Kronos Bio's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kronos Bio is 6.04x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

PMV Pharmaceuticals has a net margin of -595.27% compared to Kronos Bio's net margin of --. Kronos Bio's return on equity of -60.36% beat PMV Pharmaceuticals's return on equity of --.

Kronos Bio has a consensus price target of --, signalling upside risk potential of 125%. On the other hand PMV Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 274.19%. Given that PMV Pharmaceuticals has higher upside potential than Kronos Bio, analysts believe PMV Pharmaceuticals is more attractive than Kronos Bio.

Kronos Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PMV Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Kronos Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PMV Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kronos Bio pays -- of its earnings as a dividend. PMV Pharmaceuticals pays out -- of its earnings as a dividend.

Kronos Bio quarterly revenues are $2.4M, which are larger than PMV Pharmaceuticals quarterly revenues of --. Kronos Bio's net income of -$14.1M is higher than PMV Pharmaceuticals's net income of -$19.2M. Notably, Kronos Bio's price-to-earnings ratio is -- while PMV Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kronos Bio is 6.04x versus -- for PMV Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of -595.27% compared to Kronos Bio's net margin of -54.2%. Kronos Bio's return on equity of -60.36% beat PTC Therapeutics's return on equity of --.

Kronos Bio has a consensus price target of --, signalling upside risk potential of 125%. On the other hand PTC Therapeutics has an analysts' consensus of $57.14 which suggests that it could grow by 26.16%. Given that Kronos Bio has higher upside potential than PTC Therapeutics, analysts believe Kronos Bio is more attractive than PTC Therapeutics.

Kronos Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.619, suggesting its less volatile than the S&P 500 by 38.129%.

Kronos Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kronos Bio pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Kronos Bio quarterly revenues are $2.4M, which are smaller than PTC Therapeutics quarterly revenues of $196.8M. Kronos Bio's net income of -$14.1M is higher than PTC Therapeutics's net income of -$106.7M. Notably, Kronos Bio's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kronos Bio is 6.04x versus 3.95x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Soleno Therapeutics has a net margin of -595.27% compared to Kronos Bio's net margin of --. Kronos Bio's return on equity of -60.36% beat Soleno Therapeutics's return on equity of --.

Kronos Bio has a consensus price target of --, signalling upside risk potential of 125%. On the other hand Soleno Therapeutics has an analysts' consensus of $74.25 which suggests that it could grow by 59.82%. Given that Kronos Bio has higher upside potential than Soleno Therapeutics, analysts believe Kronos Bio is more attractive than Soleno Therapeutics.

Kronos Bio has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Soleno Therapeutics has a beta of -1.471, suggesting its less volatile than the S&P 500 by 247.077%.

Kronos Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Soleno Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kronos Bio pays -- of its earnings as a dividend. Soleno Therapeutics pays out -- of its earnings as a dividend.

Kronos Bio quarterly revenues are $2.4M, which are larger than Soleno Therapeutics quarterly revenues of --. Kronos Bio's net income of -$14.1M is higher than Soleno Therapeutics's net income of -$76.6M. Notably, Kronos Bio's price-to-earnings ratio is -- while Soleno Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kronos Bio is 6.04x versus 2,202.57x for Soleno Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.